SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001479290-20-000048
Filing Date
2020-03-26
Accepted
2020-03-26 17:04:22
Documents
7
Period of Report
2019-12-31
Effectiveness Date
2020-03-26

Document Format Files

Seq Description Document Type Size
1 DEF 14A rvnc2020proxystatementdef1.htm DEF 14A 1352324
2 ceocompensationmix2019png.jpg GRAPHIC 197030
3 marksigniture2019.jpg GRAPHIC 120509
4 psagraph2019.jpg GRAPHIC 31034
5 rvncproxycard2020page1a01.jpg GRAPHIC 402700
6 rvncproxycard2020page2a01.jpg GRAPHIC 241611
7 tobyelectronicsignature2a01.jpg GRAPHIC 96323
  Complete submission text file 0001479290-20-000048.txt   2848438
Mailing Address 7555 GATEWAY BLVD. NEWARK CA 94560
Business Address 7555 GATEWAY BLVD. NEWARK CA 94560 510-742-3400
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36297 | Film No.: 20746839
SIC: 2834 Pharmaceutical Preparations